What's New From ERA-EDTA 2018?

Slides:

Advertisements

Similar presentations

Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.

Advertisements

Diabetic nephropathy is a clinical syndrome.

Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.

Nephrology Journal Club The SPRINT Trial Parker Gregg

The Patient Experience With Systemic Lupus Erythematosus

Chronic Kidney Disease in Diabetes

Mortality rates in incident ESRD patients figure 9

Chronic HCV Infection and CKD

Diabetic Dyslipidemia in Practice

Hepatorenal Syndrome.

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

New and Emerging Management Options for Anemia in CKD

Does One Size Fit All in Obesity Management?

UNDERSTANDING RISK STRATIFICATION IN PAH:

Progression After Cancer Immunotherapy in Advanced NSCLC

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Advances in CKD.

SGLT2 Inhibitors in the Modern Era: Why and Where?

Selecting NOACs for High-Risk Patients

Optimizing Patient Outcomes in IBD

How Can we Improve Outcomes for the Elderly Patient with AML?

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Precision Management of RA and Comorbidities

The future of urate-lowering strategies for gout

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Is RA Treatment Addressing the Real Needs of Patients?

New Agents, New Regimens, New Strategies

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Oral Anticoagulation in AF

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

What's New in Therapeutic Options for Moderate to Severe RA?

Managing Rare CKDs.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

Severe Asthma and Comorbidities

Guidelines for the Older Adult With CKD

Are We Making Progress in the Management of Huntington Disease?

Oral Prostacyclin Pathway Agents in PAH

Incorporating Prostacyclins Into Practice

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Reducing Risk for CV Outcomes

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Improving Outcomes in Patients With SSc-ILD

From Adjuvant to Metastatic in Melanoma

Disease Burden of VTE Phases of VTE Treatment.

At the Crossroads of Coagulation

Third-Generation EGFR TKIs

Advances in Alport Syndrome

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Statin Selection in Patients With Pre-Diabetes: Case Considerations

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Pulmonary Arterial Hypertension and Hospitalizations

Evaluating the Totality of Evidence

Emerging Advances in Reducing Renal Complications of T2D

What's New in PAH?.

My PAH Patient.

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

NAFLD and NASH in Europe and Canada

Correlations among chronic kidney disease (CKD) classification, urinary adiponectin level, eGFR, and ACR. (A) Correlation between CKD classification and.

What's New in Rare CKDs?.

RAASi Enabling in the Modern Era

Uncovering the Right Sequence

Presentation transcript:

What's New From ERA-EDTA 2018?

Treatment Gaps in CKD

Progression of Kidney Disease Renocardiac Syndrome

Bardoxolone Phase 2 and 3 Studies in Patients With Diabetic CKD

BEACON Sustained Increase in eGFR

Exclusion of At-Risk Patients in BEACON Appears to Improve Risk-Benefit Profile of Bardoxolone

TSUBAKI Study (Japan) in Patients With Diabetic CKD

LARIAT Study Phase 2 Trial Assessing Bardoxolone in PAH

Alport Syndrome

CARDINAL Study Phase 2 Study in Patients With Alport Syndrome

PHOENIX Study Design

PHOENIX Study Initial Results From a Phase 2 Trial in Patients With ADPKD and IgA Nephropathy

Delaying Progression of Kidney Disease

Increases in Urinary Protein Are Consistent With Increases in GFR and Not Injury

Kidney Failure Outcomes

Retained Benefit After Drug Discontinuation Insights From the REPRISE Trial in ADPKD

CARDINAL Phase 3 Study Design

Long-Term Impact of Bardoxolone on Kidney?

Future Considerations for Managing Patients With CKD

Other Possible Agents Targeting Inflammation

Final Thoughts

Abbreviations

Abbreviations (cont)